Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$528.59M$528.59M+1.8% vs Q3 2020 Net Income-$7.78M-$7.78MN/M vs Q3 2020 EPS Diluted-$0.03-$0.03N/M vs Q3 2020 Gross Profit$198,511,000+48.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$82,364,000+83.9% Free Cash Flowderived$71,719,000+112.3% Margins · derivedGross margin37.6%+11.8 pt vs Q3 2020
Operating margin5.4%+4.9 pt vs Q3 2020
Net margin-1.5%+2.7 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 8, 2021 · 39 d after period end